Singapore, May 27 -- Japan-based medtech firm Olympus Corporation has signed a definitive agreement to acquire BioProtect, a medical device manufacturer aiming to advance cancer care through innovative spacing solutions. This marks an important expansion of Olympus' contributions to oncology and urology in line with its corporate strategy to accelerate cutting-edge technologies and focus on patient safety and outcomes.

The $270 million acquisition, with certain amounts held in escrow for a period dependent on uninterrupted operation of the business, is expected to be completed by the end of the second quarter of calendar year 2026, subject to customary closing conditions.

BioProtect develops implant technologies that contribute to impro...